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Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention,
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Assessment of drug susceptibility has become an integral part of influenza virus surveillance. In this study, we describe the drug
resistance profile of influenza A(H3N2) virus, A/Mississippi/05/2011, collected from a patient treated with oseltamivir and de-
tected via surveillance. AnMDCK cell-grown isolate of this virus exhibited highly reduced inhibition by the neuraminidase (NA)
inhibitors (NAIs) oseltamivir (8,005-fold), zanamivir (813-fold), peramivir (116-fold), and laninamivir (257-fold) in the NA in-
hibition assay. Sequence analysis of its NA gene revealed a known oseltamivir-resistance marker, the glutamic acid-to-valine
substitution at position 119 (E119V), and an additional change, threonine to isoleucine at position 148 (T148I). Unlike E119V,
T148I was not detected in the clinical sample but acquired during viral propagation inMDCK cells. Using recombinant proteins,
T148I by itself was shown to cause only a 6-fold increase in the zanamivir 50% inhibitory concentration (IC50) and had no effect
on inhibition by other drugs. The T148I substitution reduced NA activity by 50%, most likely by affecting the positioning of the
150 loop at the NA catalytic site. Using pyrosequencing, changes at T148 were detected in 35 (23%) of 150MDCK cell-grown
A(H3N2) viruses tested, which was lower than the frequency of changes at D151 (85%), an NA residue previously implicated in
cell selection. We demonstrate that culturing of the A(H3N2) viruses (n 11) at a lowmultiplicity of infection delayed the emer-
gence of the NA variants with changes at position 148 and/or 151, especially when conducted inMDCK-SIAT1 cells. Our findings
highlight the current challenges in monitoring susceptibility of influenza A(H3N2) viruses to the NAI class of antiviral drugs.
Neuraminidase (NA) inhibitors are the only recommended an-tiviral medications for the control of influenza virus infec-
tions due to a high level of resistance to the M2 blocker class of
antivirals (1–3). Monitoring susceptibility to NA inhibitors is a
critical component of influenza surveillance activities conducted
globally. At present, zanamivir and oseltamivir are the only NA
inhibitors approved in the United States to control influenza A
and B virus infections. Two additional NA inhibitors, laninamivir
and peramivir, have been approved for use in Japan, and perami-
vir is also marketed in South Korea and China.
Susceptibility to NA inhibitors is currently assessed by the NA
inhibition (NI) assay, which requires viruses to first be propagated
in cell culture (4). Many cell lines have been used for the propa-
gation of influenza viruses, including baby hamster kidney (BHK-
21) cells, rhesus monkey kidney epithelial (LLC-MK2) cells, and
African green monkey kidney (Vero) cells (5–8). The use of hu-
man colon intestinal epithelial (CaCo-2) cells for isolation and
propagation of seasonal A(H3N2) viruses has also been advocated
in recent years (9, 10).Madin-Darby canine kidney (MDCK) cells,
however, remain the most commonly used cell line for the prop-
agation of influenza viruses due to their superior overall sensitiv-
ity, high virus yield, and ease of culture andmaintenance (11–14).
MDCK cells express receptors with both 2-3- and 2-6
neuraminic acid (NeuAc) linkages, making them suitable for iso-
lation of a wide variety of influenza viruses (15). Indeed, MDCK
cells are routinely used for virus propagation by the Centers for
Disease Control and Prevention (CDC) Influenza Division as part
of its surveillance activities. However, the density of 2-6-linked
NeuAc receptors is lower than that of the upper respiratory epi-
thelium in humans (16), and this renders the traditional MDCK
cell-based assays unsuitable for assessing the NA inhibitor suscep-
tibility of human influenza viruses (17–19).
To address this problem, MDCK cells have been modified to
overexpress 2-6-linked NeuAc receptors (20, 21). Although this
modification did not cause MDCK-SIAT1 (SIAT1) cells to be a
reliable substrate for NA inhibitor susceptibility testing, the mod-
ified cell line was found to be advantageous for virus isolation and
propagation in a number of laboratories (22). Importantly, prop-
agation of influenza A(H3N2) viruses in MDCK cells has recently
been linked to selection of NA variants carrying substitutions at
residue D151 (23, 24). Furthermore, the D151G substitution was
shown to concurrently reduce NA catalytic activity and increase
NAbinding to2-3-linked receptors (24), switching theNA func-
tion from receptor destroying to receptor binding. The emergence
of the D151G variant has been shown to interfere with hemagglu-
tinin (HA) antigenic analysis (23), which is a critical component
of virus surveillance.
The present study demonstrates the emergence of NA variants
carrying substitutions at residue T148 as a consequence of A(H3N2)
virus culture inMDCK cells. The effects of the T148I substitution on
drug susceptibility assessment andNA catalytic activity were investi-
gated. In addition, A(H3N2) viruses were propagated and subse-
quently passaged using SIAT1 cells to determine if the emergence of
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NA variants with changes at positions 148 and 151 could be miti-
gated.
MATERIALS AND METHODS
Viruses and cells. Influenza virus isolates and their respective clinical
specimens collected during the 2010–2011 season were submitted to the
World Health Organization (WHO) Collaborating Center for Surveil-
lance, Epidemiology and Control of Influenza at the CDC for antigenic
and genetic characterization and antiviral testing. MDCK (CCL-34;
ATCC, Manassas, VA) and MDCK-SIAT1 (a kind gift fromM. Matroso-
vich) cells weremaintained by the Scientific Products and Support Branch
at the CDC. Viruses were propagated according to standard procedures as
described previously (25) withminormodifications. In brief,MDCK cells
seeded in T75 flasks were inoculated with 0.6 ml of a clinical specimen,
and following 1 h of virus adsorption, 20 ml of Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 0.2% bovine serum albumin
(BSA), 100 g/ml streptomycin, 100 U/ml penicillin, and 2 g/ml tosyl-
sulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin was added to
the flask. The cells were observed for cytopathic effect (CPE), and the
supernatants were harvested no later than 6 days postinoculation. If the
HA titer was insufficient to conduct anHA inhibition assay, an additional
passage was performed up to four passages in total.
In this study, a modified procedure was used to isolate viruses from
clinical specimens and to perform further passage. MDCK and SIAT1 cell
monolayers in T25 flasks were washed twice with phosphate-buffered
saline (PBS). The clinical specimen (100 l) was diluted in 900 l of PBS
and added to the flask. After a 1-h virus adsorption at 37°C, the inoculum
was removed, the cells were washed twice with PBS, and 7 ml of supple-
mentedDMEM (see above) was added to the flask. The infected cells were
incubated at 37°C in a humidified 5% CO2 atmosphere for 6 days and
monitored daily for CPE.When the CPE reached 25 to 50%, the superna-
tants were harvested and clarified by low-speed centrifugation (see Table
S1 in the supplemental material). Aliquots were stored at 80°C before
testing. Viral HA titers were determined by a standard procedure using
guinea pig red blood cells. Infectious-virus titers were determined by lim-
iting dilution in SIAT1 cells and calculated using the Spearman-Karber
method (26). A subsequent passage was carried out at a multiplicity of
infection (MOI) equal to 0.001 50% tissue culture infective dose (TCID50)
per cell in a T25 flask.
The CDC reference A(H3N2) virus A/Texas/12/2007 variant carrying
the oseltamivir resistance marker, E119V, in the NA and A/Washington/
01/2007 wild-type virus were used as controls in the NI assay.
Fisher’s exact tests to compare the proportions of neuraminidase vari-
ants that emerged at positions T148 and D151 after subsequent passages
using different procedures and cell lines were performed using SAS ver-
sion 9.3 (SAS Institute, Cary, NC) at a significance level wherewas equal
to 0.05. P values of0.05 were considered statistically significant.
Susceptibility to NA inhibitors. Propagated virus isolates were tested
using the fluorescent NI assay with an NA-Fluor kit (Applied Biosystems,
Carlsbad, CA, USA), as described previously (27). Four NA inhibitors,
zanamivir (GlaxoSmithKline, Uxbridge, United Kingdom), oseltamivir
carboxylate (F. Hoffmann-La Roche Ltd., Basel, Switzerland), peramivir
(BioCryst Pharmaceuticals, Durham, NC), and laninamivir (R-125489;
Biota, Victoria, Australia), were utilized. The IC50 (the drug concentra-
tion required to inhibit NA activity by 50%) was determined using JASPR
v1.2, CDC-developed curve-fitting software, as described previously (27).
Means and standard deviations (SD) were calculated from results col-
lected from at least three independent tests.
Criteria set by the WHO Antiviral Working Group (AVWG) were
used for interpretation of IC50s (28). Briefly, for influenza type A viruses,
an increase in the IC50 compared to a susceptible reference virus of10-
fold corresponds to normal inhibition, an IC50 with a 10- to 100-fold
increase corresponds to reduced inhibition, and a 100-fold increase is
equal to highly reduced inhibition.
Sequence analysis.Conventional sequence analysis of theNAgene for
A/Mississippi/05/2011 (clinical specimen, passage 2 [P2], and P3) was
performed by the Sequencing Activity Team of the Influenza Division at
the CDC, as described previously (29). In addition, the HA and NA gene
sequenceswere generated for a subset of A(H3N2) clinical specimens (n
11) and their respective isolates passaged five times in MDCK cells with
the use of a primer set (see Table S2A in the supplemental material).
Reverse transcription (RT)-PCR amplicons were treated with ExoSap-It
reagent following themanufacturer’s recommendations (USB, Cleveland,
OH) and used as templates in sequencing reactions with an ABI Prism
BigDye Terminator kit (Applied Biosystems, Foster City, CA). The prod-
ucts of the sequencing reactions were treated with XTerminator solution
(Applied Biosystems, Foster City, CA) according to the manufacturer’s
protocol. Sequences generated in an ABI Prism 3730 genetic analyzer
(Applied Biosystems, Foster City, CA) were assembled into fragment-
specific contigs using Lasergene software, version 7.0 (DNAStar, Madi-
son, WI).
Pyrosequencing. Viral-RNA extraction, RT-PCR, and pyrosequenc-
ing were performed as previously described (30). Pyrosequencing was
performed using the PyroMark PSQ96MA instrument (Qiagen, Valencia,
CA). The RT-PCR and sequencing primers for analysis of the residue at
position 119 in NA (see Table S2B in the supplemental material) were
previously described (30). A set of primers for the analysis of residues 148
and 151 inNAwere designedwith the use of PyrosequencingAssayDesign
software (Qiagen, Valencia, CA). Pyrosequencing with customized nucle-
otide dispensation order was used to detect variants with changes at
codons 148 and 151 (29). The nucleotide dispensation AGTAGCACATA
GTCACGATCATCGTCTATCA(GATC)5 enabled identification of the
following NA variants: threonine (T; nucleotide sequence ACA), lysine
(K; nucleotide sequence AAA), or isoleucine (I; nucleotide sequence
ATA) at position 148 and aspartic acid (D; nucleotide sequence GAT),
glycine (G; nucleotide sequence GGT), or asparagine (N; nucleotide se-
quence AAT) at position 151. Single-nucleotide polymorphism (SNP)
analysis was done essentially as previously described (29) with the limit of
detection set at 10%.
Generation of recombinant NAs. A codon-optimized cDNA encod-
ing the ectodomain (residues 82 to 469) of the NA gene of A/Perth/10/
2010 (H3N2) (Life Technologies, NY) was subcloned into the pIEx-4
vector (EMD Millipore, MA) using the In-Fusion HD cloning system
(Clontech, CA). All subsequent NA mutants (E119V, T148I, and E119V/
T148I) were generated from this wild-type pIEx-4-NA clone using a
QuikChange Lightning site-directed mutagenesis kit (Agilent, CA). The
resulting constructs were transiently transfected into sf9 cells (EMDMil-
lipore, MA) using the Cellfectin II transfection reagent (Life Technolo-
gies, NY) according to the manufacturer’s protocols. Five days posttrans-
fection, the supernatant containing secreted recombinantN2NA (recNA)
was harvested and clarified, and the recNAwas quantified byWestern blot
analysis, using baculovirus-produced/purified A/Perth/16/2009 NA pro-
tein as a control. The supernatants were assessed for functional activity
using theMUNANA assay (27) and analyzed without further purification
in neuraminidase inhibition assays.
Nucleotide sequence accession numbers. The sequences of the NA
genes for A/Mississippi/05/2011 (clinical specimen, P2, and P3) were de-
posited at the Global Initiative on Sharing All Influenza Data (GISAID),
and the accession numbers are given in Table 1. The HA and NA gene
sequences for a subset of A(H3N2) clinical specimens (n  11) were
deposited at GISAID, and the accession numbers are given in Table 2 and
also in Table S3 in the supplemental material.
RESULTS
Detection of an oseltamivir-resistant A(H3N2) virus. To moni-
tor influenza virus susceptibility to NA inhibitors, MDCK cell-
grown viruses are tested in the fluorescent NI assay. Among the
influenza A(H3N2) viruses tested (n  1,777) during the 2010–
2011 season, one virus, A/Mississippi/05/2011 (0.06%), exhibited
Tamura et al.
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a 726-fold increase in oseltamivir IC50 compared to that of the
CDC reference drug-sensitive control, A/Washington/01/2007
A(H3N2) virus (Table 1). Sequence analysis of the NA gene of
A/Mississippi/05/2011 (P2) revealed the presence of the E119V
substitution, a known marker of oseltamivir resistance in
A(H3N2) viruses (4). To enable further studies, A/Mississippi/05/
2011 (P2) was passaged an additional time, and the P3 isolate was
tested in theNI assay. The P3 isolate not only exhibited a very high
oseltamivir IC50 (8,005-fold), it also showed100-fold increases
in the IC50s of the remaining three NA inhibitors, zanamivir,
peramivir, and laninamivir (Table 1). According to the WHO
AVWG criteria (28), this result would be interpreted as “highly
reduced” inhibition of all four NA inhibitors tested. Notably, NA
sequence analysis of the P3 isolate revealed an additional substi-
tution, T148I (nucleotide change, ACA¡ATA). To determine if
either of the NA substitutions detected in the P3 isolate was pres-
ent in the clinical specimen, a pyrosequencing assay was per-
formed. The E119V NA variant was detected in the clinical speci-
men and the P2 and P3 isolates (72%, 100%, and 100%,
respectively). In contrast, no changes at position 148 were de-
tected in the clinical specimen, while T148I was present at 65%
and at 100% in the P2 and P3 isolates (Table 1). Taken together
these data demonstrate that two events had occurred during virus
propagation in MDCK cells, an increase in the proportion of the
oseltamivir-resistant E119V NA variant and the emergence of the
T148I NA variant.
Frequencies ofNA substitutions at T148 andD151 inMDCK
cell-grown viruses. To assess the frequency of changes at T148 in
cell-cultured viruses, NA sequences for A(H3N2) viruses collected
globally in the 2010–2011 influenza season and deposited at the
GISAID were analyzed. The NA variants with I, K, P, S, or M at
residue 148, either alone or in a mixture with the wild type, were
detected in 121 (8.8%) of 1,370 sequences analyzed. Because the
conventional sequencing is not sufficiently sensitive at detecting
viral subpopulations, the pyrosequencing assay was used for the
analysis. To this end, the NA sequences of 150 viruses that had
undergone between one and four passages inMDCK cells prior to
testing (see Table S4 in the supplemental material) were analyzed
by pyrosequencing. The analysis revealed that 35 of the 150 (23%)
contained an amino acid substitution at codon T148 (I, K, or P),
either alone or in a mixture with the wild type (see Table S4). In
addition, an even a greater number of NA sequences (85%)
showed variance at residue D151 (see Table S4). It has previously
been shown that the substitution D151G alters the properties of
the viral NA by reducing catalytic activity while increasing the
binding affinity for2,3-sialosides (24). Therefore, it is not unrea-
sonable to expect that the emergence of NA variants with substi-
tution at T148mayhave a similar underlyingmechanism.Accord-
ingly, we hypothesized that two approaches are likely to put the
unwanted T148I and D151G variants at a selective disadvantage:
(i) using a lower MOI and (ii) using MDCK cells modified to
overexpress 2,6 receptors (SIAT1 cells).
Comparative analysis of MDCK cell- and SIAT1 cell-grown
isolates.To test our assumptions, a subset of the A(H3N2) viruses
from the 2010–2011 season were studied in detail. Nine (75%) of
12 viruses cultured in MDCK cells for a total of 1 to 3 passages
using the standard procedure showed the NA sequence variances
at position 148 and/or 151 (Table 2). Their respective clinical
specimens were then used to reisolate viruses on bothMDCK and
TABLE 1 Characterization of the A/Mississippi/05/2011(H3N2) virus passaged on MDCK cells
A(H3N2) virus name
Mean IC50 SD
a [nM (foldb)] NA residue (%)c
Zanamivir Oseltamivir Peramivir Laninamivir 119 (E/V) 148 (T/I)
A/Mississippi/05/2011 (P0)d NAe NA NA NA 28/72 100/0
A/Mississippi/05/2011 (P2) 1.19 0.01 (5) 65.36 13.07 (726) 0.20 0.01 (2) 0.79 0.08 (3) 0/100 35/65
A/Mississippi/05/2011 (P3) 195.00 7.47 (813) 720.45 57.71 (8,005) 10.42 1.34 (116) 71.85 3.63 (257) 0/100 0/100
Reference viruses
A/Washington/01/2007 0.24 0.01 0.09 0.01 0.09 0.01 0.28 0.03 100/0 57/43
A/Texas/12/2007 (E119V),
oseltamivir resistant
0.40 0.02 45.48 9.70 (505) 0.11 0.01 0.34 0.03 0/100 100/0
a Based on at least three independent experiments.
b Fold increase based on comparison to the respective IC50s of the reference virus, A/Washington/01/2007.
c Proportion of NA variants determined using SNP pyrosequencing analysis.
d P0, clinical specimen; P2 and P3, virus isolates passaged two and three times, respectively, on MDCK cells using the standard procedure. The GISAID accession numbers for the
NA genes are EPI408578, EPI366355, and EPI408583.
e NA, not applicable; neuraminidase inhibition testing was not performed on the clinical specimen.
TABLE 2 Substitutions at positions 148 and 151 in the neuraminidase
of a subset of A(H3N2) viruses propagated on MDCK cells according to
the standard procedure used in routine surveillance
Virus
IDa Virus name
GISAID
accession
no.b
Final
passage
no.
Substitution
at residue:
148 151
1 A/Alaska/13/2011 EPI438310 1 c 
2 A/American Samoa/7415/2011 EPI438318 1 T/Id D/Ne
3 A/American Samoa/7102/2011 EPI438314 1 T/I D/G
4 A/Vermont/17/2011 EPI438350 2 T/I 
5 A/Texas/18/2011 EPI438338 2 T/I D/G/N
6 A/Arizona/07/2011 EPI438322 2 T/I D/G
7 A/Texas/24/2010 EPI438342 2  
8 A/Pennsylvania/03/2011 EPI438334 2  
9 A/Utah/09/2011 EPI438346 2 T/I D/G
10 A/New York/11/2011 EPI438330 2 I 
11 A/Nebraska/12/2011 EPI438326 3 I 
12 A/Mississippi/05/2011 EPI408578 3 I 
a The virus identifiers (IDs) correspond to those in Table 3 and in Tables S3 and S5 in
the supplemental material.
b NA gene sequences of viruses in the clinical specimen.
c, no changes observed (wild type).
d T/I, mixture of threonine and isoleucine at position 148.
e D/N, mixture of aspartic acid and asparagine at position 151.
Cell-Selected Influenza Virus NA Variants
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SIAT1 cells using the modified procedure described in Materials
and Methods. Following each passage, the cell culture superna-
tants were harvested and tested to determine the infectious-virus
titers, HA titers, NA sequences at residues 148 and 151, and IC50s
for four NA inhibitors in the fluorescent NI assay.
Eleven of 12 viruses were successfully reisolated in both cell
lines and were passaged five times (Table 3). TheMDCK cell- and
SIAT1 cell-grown viruses produced similar infectious-virus titers
ranging from 5.9 to 9.2 log10 TCID50/ml (see Table S5A and B in
the supplemental material). Consistent with our hypothesis, no
changes at either residue 148 or 151 were detected in any SIAT1
cell-grown virus, with the exception of the D151G NA substitu-
tion (40% by SNP) detected in a single virus (no. 11) after the last
passage (Table 3). Notably, the emergence of the NA variants was
also delayed when themodified procedure was used to culture the
viruses in MDCK cells. After the first passage, no substitutions at
either position 148 or 151 were detected in any of the isolates
(Table 3). By the second passage, the T148I substitution was de-
tected in a single isolate (no. 2), and the third passage yielded four
(36%) viruses with changes at position 148. Peculiarly, the NA
variants detected in three P3 and one P4 isolates (no. 1, 3, 10, and
11) were not found after further passaging. After the fifth passage,
five isolates contained NA variants at residue T148 but none at
residue 151. Two viruses (no. 4 and 5) retainedwild-type sequence
at both residues 148 and 151 for all passages using the modified
procedure, while the same two viruses had changes at residue 148
and/or 151 when propagated under the standard procedure. In
some instances, besides the delayed emergence, there was also a
difference in the substituted residue. For example, the passaging of
two viruses (no. 10 and 11) resulted in the emergence of the T148I
variant using the standard procedure, while the D151G variant
emerged when culture was performed using a low MOI. To thor-
oughly compare the P5 isolates to their respective clinical speci-
mens, sequencing was performed, and no additional changes in
the NA were detected besides those identified by pyrosequencing.
Overall, after three passages in MDCK cells, a significantly
lower number of mutants emerged at both residues T148 (P 
0.0003) and D151 (P 0.043) using the modified procedure than
using the standard procedure. In the modified procedure, after
five passages, a significantly lower number of mutants emerged at
residue T148 in MDCK-SIAT1 cells than in MDCK cells (P 
0.0001); there was no significant difference in the proportions of
mutants that emerged at residue D151 (P 0.05).
To assess the potential effect of virus culture on drug suscepti-
bility, supernatants collected after each passage in both cell lines
(n 110) were grouped according to their sequences at residues
148 and 151 and tested in the NI assay. When present either alone
or in amixture with the wild type, the I148 NA variant displayed a
slight increase in zanamivir IC50s, although it was not statistically
significant (see Table S6 in the supplemental material). The com-
bination of T148K/I was accompanied by the highest increase (7-
fold) in zanamivir IC50s.Meanwhile, T148I had no apparent effect
on the IC50s for oseltamivir, peramivir, and laninamivir (data not
shown).
Despite the overall similarities in the infectious-virus titers, the
HA titers of several MDCK cell-grown viruses were greater than
those of their SIAT1 cell-grown counterparts (see Table S5A andB
in the supplementalmaterial). One SIAT1 cell-grown virus (no. 2)
produced no agglutination of guinea pig red blood cells despite
the high infectious titers, whereas its MDCK cell-grown counter-
part had relatively high HA titers, with the substitution T148I in
the NA. With the exception of a single virus (no. 8 contained
P221L), no amino acid differences in the HA of the MDCK cell-
grown viruses compared to their respective clinical specimens
were detected. Therefore, the increase in the HA titers of the
MDCK cell-grown viruses often coincided with the emergence of
theNAvariants (see Table S5A in the supplementalmaterial). This
observation supports the proposed role of the 148 substitution in
the NA ability to bind to NeuAc-containing receptors.
Properties of recombinantNAs.To ascertain the role of T148I
in the observed elevated IC50s, recNA of A/Perth/10/2010—an
NA identical to that of A/Mississippi/05/2011 except for their dif-
TABLE 3 Substitutions at positions 148 and 151 in the neuraminidase of a subset of A(H3N2) viruses passaged on MDCK and MDCK-SIAT1 cells
using modified procedures
Virus
ID
Substitution using modified procedure
MDCK cells MDCK-SIAT1 cells
P1 P2 P3 P4 P5 P1 P2 P3 P4 P5
148 151 148 151 148 151 148 151 148 151 148 151 148 151 148 151 148 151 148 151
1 a     D/Gb              
2   T/Ic  I  I  I           
3      D/N              
4                    
5                    
6     T/I/K  I/K  I/K           
7     T/I D/G T/I  I           
8       T/K  T/K           
9     T/I  T/I  I           
10      D/G              
11        D/G            D/G
12 NDd ND
a No changes observed (wild type).
b D/G, mixture of aspartic acid and glycine at position 151.
c T/I, mixture of threonine and isoleucine at position 148.
d ND, not done; the attempt to reisolate the virus failed.
Tamura et al.
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ference at position 464 (I464L)—and its subsequentmutants pos-
sessing E119V and/or T148I substitutions were generated and
tested in theNI assay. The recNAT148I displayed slightly elevated
zanamivir and laninamivir IC50s—6- and 3-fold, respectively—
and unaltered IC50s for the other two NA inhibitors (Table 4). As
anticipated, the recNA E119V showed a 281-fold increase in the
oseltamivir IC50, whereas the IC50s of the other three NA inhibi-
tors were either unchanged or slightly elevated (1- to 4-fold). No-
tably, the recNA E119V-T148I exhibited highly elevated IC50s of
all fourNA inhibitors, ranging from119- to 6,154-fold, depending
on the drug (Table 4). The T148I substitution also caused a 50%
reduction in NA activity, and the detrimental effect was even
greater (loss of 96% of activity) when this substitution was com-
bined with E119V (data not shown).
DISCUSSION
In the present study, we demonstrate that culturing influenza
A(H3N2) viruses inMDCK cells can alter their drug susceptibility
phenotypes. The oseltamivir-resistant A(H3N2) E119V virus was
identified among viruses submitted for virological surveillance,
and when tested in the NI assay, its P3 isolate displayed cross-
resistance to four NA inhibitors tested (oseltamivir, zanamivir,
peramivir, and laninamivir). This unusual observation prompted
us to further investigate the properties of the virus and led to
discovery of the role played by the T148I substitution identified in
its NA. Unlike the oseltamivir-selected E119V, T148I was not de-
tected in the clinical specimen andwas shown to be a consequence
of the virus propagation in MDCK cells.
Substitutions at two other residues, 136 and 151, in the NA of
A(H1N1) have been shown to affect drug NA inhibitor suscepti-
bility and were linked to influenza virus propagation in MDCK
cells (31, 32). Moreover, previous studies have shown that the
MDCK cell-grown A(H3N2) virus contained substitutions at po-
sitions 148 and 151, whereas its counterpart propagated in
CaCo-2 cells did not have such changes (10). Despite the growing
evidence regarding selection of NA variants in MDCK cells, the
cell line continues to be the most common substrate for the prop-
agation of human influenza viruses.
In this study, two simple approaches tomitigate the emergence
of NA variants during culture were explored. Propagation of
A(H3N2) viruses was conducted at a low MOI (modified proce-
dure) on both MDCK and SIAT1 cells. Experimental evidence
that the low MOI (0.001) was sufficient to delay the NA variant
emergence on MDCK cells was provided. The result was even
better if isolation andpropagationwere carried out on SIAT1 cells.
However, concerns have arisen that SIAT1 cells may select for HA
variants of A(H1N1)pdm09 viruses with altered antigenic prop-
erties and thus may not be a suitable culture for propagation of all
influenza viruses (33). For the set of A(H3N2) viruses analyzed in
this study, similarly high infectious titers (ranging from 5.9 to 9.2
log10 TCID50/ml) were achieved in both cell lines, and the NA
activities were sufficient to determine drug susceptibilities in the
NI assay. However, the HA titers of certain SIAT1 cell-grown vi-
ruses were lower than those of the MDCK cell-grown viruses,
whichmay preclude their testing in theHI assays.Notably,MDCK
cell-grown viruses that acquired changes at position 148 displayed
HA titers higher than those of their SIAT1 cell-grown counter-
parts. This observation indirectly supports the role of this substi-
tution in the increased NA binding to NeuAc-containing recep-
tors. Unlike the D151G substitution (24), the mechanism by
which the T148I substitutionmay increase NA binding to NeuAc-
containing receptors is unknown. The T148I change not only in-
troduces a hydrophobic residue that could structurally affect the
nearby active site, it also results in the loss of a potential glyco-
sylation site at N146. Interestingly, alignment of contemporary
NA sequences from the GISAID database revealed no virus with a
substituted N146.
Further experimental evidencewas obtainedwith the use of the
recNA proteins. The recNA carrying both E119V and T148I
changes showed highly reduced inhibition by all NA inhibitors
and a drastic loss of NA activity. T148I alone was associated with a
slight increase (6-fold) in the zanamivir IC50 while showing little
or no effect on inhibition by the other three NA inhibitors; it
caused a loss of 50% of NA activity towardMUNANA. NA inhib-
itors compete withNeuAc-containing receptors for binding to the
NA active site. Zanamivir was designed using a minimalistic ap-
proach (34) andmost closely resembles the structure of NeuAc. It
is not surprising, therefore, that zanamivir bindingwas affected by
the T148I substitution.
NA variants with changes at positions 148 and 151 often pres-
ent as a mixture with the wild type, and their presence could be
underreported if conventional sequencing was employed. In this
regard, the pyrosequencing assay used in this study offers a supe-
riormeans to detect and identify minor subpopulations, although
it requires highly skilled technical personnel (35).
Our results support the notion that culture of A(H3N2) viruses
needs to be carried out at a low MOI whenever possible, and the
number of passages should be kept to aminimum. This rule needs
to be applied when analyzing samples collected fromNA inhibitor
clinical trials or when preparing reference viruses used for valida-
tion of NI assays. For example, the T148I substitution (	43% by
SNP pyrosequencing) was detected in the CDC reference drug-
sensitive A/Washington/01/2007 A(H3N2) virus used in this
study. Additional efforts should be made to identify suitable cell
cultures that do not exert selective pressure on human influenza
TABLE 4 IC50s of recombinant neuraminidases tested in the fluorescent NI assay
NA substitution
Mean IC50 SD
a [nM (foldb)]
Zanamivir Oseltamivir Peramivir Laninamivir
E119V 0.54 0.13 (3) 44.93 3.76 (281) 0.12 0.02 (1) 0.43 0.08 (4)
T148I 1.33 0.16 (6) 0.04 0.00 (1) 0.06 0.00 (1) 0.34 0.02 (3)
E119V, T148I 220.48 14.00 (1,050) 984.62 76.60 (6,154) 9.54 1.67 (119) 79.47 10.30 (722)
None 0.21 0.03 0.16 0.07 0.08 0.01 0.11 0.04
a Based on at least three independent experiments.
b Fold change based on comparison to the respective IC50 values of recNA E119 and T148 (wild type).
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viruses that may lead to altered antigenic and drug resistance phe-
notypes.
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